This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
発熱性好中球減少症
高 松 泰
Key words : Febrile neutropenia, Empiric therapy, Prophylaxis
肺疾患を伴う場合をあげている3)。また AmericanSociety of Clinical Oncology(ASCO)のガイドラインでは,患者の背景,基礎疾患(がんの種類),がん薬物療
法の種類に応じて FN を起こすリスクを提示している(表 1)10)。
FNが起こった場合に重症化する危険性を評価するには,Multinational Association of Supportive Care in Can-cer(MASCC)スコアが広く使用されている。スコアの合計が 21点以上の場合は低リスク,20点以下は高リスクと判断される(表 2)11)。ただし MASCC スコアだけで FNに対する外来治療が可能かどうかを判断するのは困難で,ASCOガイドラインでは,MASCCスコアが 21点以上であっても FNに対して外来治療を行うべきでない臨床的基準を提示している(表 3)10)。
1)Pillay J, den Braber I, Vrisekoop N, et al. In vivo labeling with2H2O reveals a human neutrophil lifespan of 5.4 days. Blood.2010; 116: 625-627.
2)Klastersky J. Management of fever in neutropenic patientswith different risks of complications. Clin Infect Dis. 2004; 39Suppl 1: S32-S37.
3)Freifeld AG, Bow EJ, Sepkowitz KA, et al. Infectious DiseasesSociety of America. Clinical practice guideline for the use ofantimicrobial agents in neutropenic patients with cancer:2010 update by the infectious diseases society of America.Clin Infect Dis. 2011; 52: e56-e93.
4)Klastersky J. Febrile neutropenia. Curr Opin Oncol. 1993; 5:625-632.
5)Lepage E, Gisselbrecht C, Haioun C, et al. Prognostic signifi-cance of received relative dose intensity in non-Hodgkin< slymphoma patients: application to LNH-87 protocol. TheGELA. (Groupe d<Etude des Lymphomes de l<Adulte). AnnOncol. 1993; 4: 651-656.
6)Bosly A, Bron D, Van Hoof A, et al. Achievement of optimalaverage relative dose intensity and correlation with survivalin diffuse large B-cell lymphoma patients treated with CHOP.Ann Hematol. 2008; 87: 277-283.
7)Hughes WT, Armstrong D, Bodey GP, et al. From theInfectious Diseases Society of America. Guidelines for theuse of antimicrobial agents in neutropenic patients withunexplained fever. J Infect Dis. 1990; 161: 381-396.
9)Masaoka T. Evidence-based recommendations on antimicro-bial use in febrile neutropenia in Japan. Int J Hematol. 1998;68: S5-S6.
10)Flowers CR, Seidenfeld J, Bow EJ, et al. Antimicrobialprophylaxis and outpatient management of fever andneutropenia in adults treated for malignancy: AmericanSociety of Clinical Oncology clinical practice guideline. J ClinOncol. 2013; 31: 794-810.
11)Klastersky J, Paesmans M, Rubenstein EB, et al. The
Multinational Association for supportive care in cancer riskindex: a multinational scoring system for identifying low-riskfebrile neutropenic cancer patients. J Clin Oncol. 2000; 18:3038-3051.
12)Kang CI, Kim SH, Kim HB, et al. Pseudomonas aeruginosabacteremia: risk factors for mortality and influence of delayedreceipt of effective antimicrobial therapy on clinical outcome.Clin Infect Dis. 2003; 37: 745-751.
13)Yoshida M, Akiyama N, Fujita H, et al. Analysis ofbacteremia/fungemia and pneumonia accompanying acutemyelogenous leukemia from 1987 to 2001 in the Japan AdultLeukemia Study Group. Int J Hematol. 2011; 93: 66-73.
14)Biron P, Fuhrmann C, Cure H, et al. Cefepime versusimipenem-cilastatin as empirical monotherapy in 400 febrilepatients with short duration neutropenia. CEMIC (StudyGroup of Infectious Diseases in Cancer). J AntimicrobChemother. 1998; 42: 511-518.
15)Wang FD, Liu CY, Hsu HC, et al. A comparative study ofcefepime versus ceftazidime as empiric therapy of febrileepisodes in neutropenic patients. Chemotherapy. 1999; 45:370-379.
16)Tamura K, Matsuoka H, Tsukada J, et al. Kyushu Hematolo-gy Organization for Treatment (K-HOT) Study Group.Cefepime or carbapenem treatment for febrile neutropenia asa single agent is as effective as a combination of 4th-generation cephalosporin + aminoglycosides: comparativestudy. Am J Hematol. 2002; 71: 248-255.
17)Freifeld AG, Walsh T, Marshall D, et al. Monotherapy forfever and neutropenia in cancer patients: a randomizedcomparison of ceftazidime versus imipenem. J Clin Oncol.1995; 13: 165-176.
18)Cherif H, Bjorkholm M, Engervall P, et al. A prospective,randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia inpatients treated for haematological malignancies. Scand JInfect Dis. 2004; 36: 593-600.
19)Feld R, DePauw B, Berman S, et al. Meropenem versusceftazidime in the treatment of cancer patients with febrileneutropenia: a randomized, double-blind trial. J Clin Oncol.2000; 18: 3690-3698.
20)Bow EJ, Rotstein C, Noskin GA, et al. A randomized, open-label, multicenter comparative study of the efficacy and safetyof piperacillin-tazobactam and cefepime for the empiricaltreatment of febrile neutropenic episodes in patients withhematologic malignancies. Clin Infect Dis. 2006; 43: 447-459.
21)Bauduer F, Cousin T, Boulat O, et al. A randomized prospec-tive multicentre trial of cefpirome versus piperacillin-tazobactam in febrile neutropenia. Leuk Lymphoma. 2001;42: 379-386.
22)Ichikawa M, Suzuki D, Ohshima J, et al. Piperacillin/tazobactam versus cefozopran for the empirical treatment ofpediatric cancer patients with febrile neutropenia. Pediatr
臨 床 血 液 54:10
475(2021)
Blood Cancer. 2011; 57: 1159-1162.23)Sato T, Kobayashi R, Yasuda K, Kaneda M, Iguchi A,
Kobayashi K. A prospective, randomized study comparingcefozopran with piperacillin-tazobactam plus ceftazidime asempirical therapy for febrile neutropenia in children withhematological disorders. Pediatr Blood Cancer. 2008; 51:774-777.
24)Nomura K, Morikawa N, Ikawa K, et al. Optimized dosageand frequency of cefozopran for patients with febrileneutropenia based on population pharmacokinetic andpharmacodynamic analysis. J Antimicrob Chemother. 2008;61: 892-900.
25)Ikeda K, Morikawa N, Kuribayashi M, Ikawa K, Nomura K,Taniwaki M. Real-time therapeutic drug monitoring ofcefozopran in plasma using high-performance liquid chroma-tography with ultraviolet detection. J Pharm Biomed Anal.2007; 45: 811-816.
26)Nakagawa Y, Suzuki K, Hirose T, et al. Clinical efficacy andsafety of biapenem for febrile neutropenia in patients withunderlying hematopoietic diseases: a multi-institutionalstudy. J Infect Chemother. 2011; 17: 58-67.
27)Kwon KT, Cheong HS, Rhee JY, et al. Panipenem versuscefepime as empirical monotherapy in adult cancer patientswith febrile neutropenia: a prospective randomized trial. Jpn JClin Oncol. 2008; 38: 49-55.
28)Marcus R, Paul M, Elphick H, Leibovici L. Clinicalimplications of b-lactam-aminoglycoside synergism: system-atic review of randomised trials. Int J Antimicrob Agents.2011; 37: 491-503.
29)Paul M, Soares-Weiser K, Leibovici L. b lactam monotherapyversus b lactam-aminoglycoside combination therapy forfever with neutropenia: systematic review and meta-analysis.BMJ. 2003; 326: 1111.
30)Vardakas KZ, Samonis G, Chrysanthopoulou SA, Bliziotis IA,Falagas ME. Role of glycopeptides as part of initial empiricaltreatment of febrile neutropenic patients: a meta-analysis ofrandomised controlled trials. Lancet Infect Dis. 2005; 5: 431-439.
31)Kern WV. Risk assessment and treatment of low-risk patientswith febrile neutropenia. Clin Infect Dis. 2006; 42: 533-540.
32)Obayashi T, Yoshida M, Mori T, et al. Plasma (1- ->3)-b-D-glucan measurement in diagnosis of invasive deep mycosisand fungal febrile episodes. Lancet. 1995; 345: 17-20.
33)Herbrecht R, Letscher-Bru V, Oprea C, et al. Aspergillusgalactomannan detection in the diagnosis of invasiveaspergillosis in cancer patients. J Clin Oncol. 2002; 20: 1898-1906.
34)Caillot D, Couaillier JF, Bernard A, et al. Increasing volumeand changing characteristics of invasive pulmonary aspergil-losis on sequential thoracic computed tomography scans in
patients with neutropenia. J Clin Oncol. 2001; 19: 253-259.35)Gorschlüter M, Mey U, Strehl J, et al. Neutropenic
enterocolitis in adults: systematic analysis of evidencequality. Eur J Haematol. 2005; 75: 1-13.
36)Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphoteri-cin B for empirical therapy in patients with persistent feverand neutropenia. National Institute of Allergy and InfectiousDiseases Mycoses Study Group. N Engl J Med. 1999; 340:764-771.
37)Boogaerts M, Winston DJ, Bow EJ, et al. ItraconazoleNeutropenia Study Group. Intravenous and oral itraconazoleversus intravenous amphotericin B deoxycholate as empiricalantifungal therapy for persistent fever in neutropenic pa-tients with cancer who are receiving broad-spectrumantibacterial therapy. A randomized, controlled trial. AnnIntern Med. 2001; 135: 412-422.
38)Walsh TJ, Pappas P, Winston DJ, et al. National Institute ofAllergy and Infectious Diseases Mycoses Study Group.Voriconazole compared with liposomal amphotericin B forempirical antifungal therapy in patients with neutropenia andpersistent fever. N Engl J Med. 2002; 346: 225-234.
39)Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versusliposomal amphotericin B for empirical antifungal therapy inpatients with persistent fever and neutropenia. N Engl J Med.2004; 351: 1391-1402.
40)Tamura K, Urabe A, Yoshida M, et al. Efficacy and safety ofmicafungin, an echinocandin antifungal agent, on invasivefungal infections in patients with hematological disorders.Leuk Lymphoma. 2009; 50: 92-100.
41)Walsh TJ, Anaissie EJ, Denning DW, et al. InfectiousDiseases Society of America. Treatment of aspergillosis:clinical practice guidelines of the Infectious Diseases Societyof America. Clin Infect Dis. 2008; 46: 327-360.
42)Pappas PG, Kauffman CA, Andes D, et al. Infectious DiseasesSociety of America. Clinical practice guidelines for themanagement of candidiasis: 2009 update by the InfectiousDiseases Society of America. Clin Infect Dis. 2009; 48: 503-535.
43)Raad I, Hanna HA, Alakech B, Chatzinikolaou I, Johnson MM,Tarrand J. Differential time to positivity: a useful method fordiagnosing catheter-related bloodstream infections. AnnIntern Med. 2004; 140: 18-25.
44)Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update ofrecommendations for the use of white blood cell growthfactors: an evidence-based clinical practice guideline. J ClinOncol. 2006; 24: 3187‒3205.
45)Engels EA, Lau J, Barza M. Efficacy of quinolone prophylaxisin neutropenic cancer patients: a meta-analysis. J Clin Oncol.1998; 16: 1179-1187.